Neu­ro­crine adds a Parkin­son’s drug to its late-stage pipeline in $145M deal

With one drug un­der re­view at the FDA, Neu­ro­crine Bio­sciences $NBIX is fol­low­ing up with a deal to in-li­cense a new ther­a­py it can add to the late-stage pipeline.

The San Diego-based biotech turned to Por­tu­gal’s Bial for North Amer­i­can rights to On­gen­tys (op­i­capone), a once-dai­ly COMT in­hibitor ap­proved in Eu­rope as an ad­junc­tive ther­a­py for Parkin­son’s dis­ease.

Bial is get­ting $30 mil­lion up­front and up to $115 mil­lion in mile­stones in the deal. And once the deal is done, Neu­ro­crine ex­ecs plan to sit down with the FDA and talk about a new drug ap­pli­ca­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.